Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: Identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-Fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1- ylbutyl) Urea (SEN34625/WYE-103914)

Journal of Medicinal Chemistry

Volumn 53, Issue 11, 2010, Pages 4379-4389

  Ghiron, Chiara ^a   Haydar, Simon N ^b   Aschmies, Suzan ^b   Bothmann, Hendrick ^a   Castaldo, Cristiana ^a   Cocconcelli, Giuseppe ^a   Comery, Thomas A ^b   Di, Li ^b   Dunlop, John ^b   Lock, Tim ^b   Kramer, Angela ^b   Kowal, Dianne ^b   Jow, Flora ^b   Grauer, Steve ^b   Harrison, Boyd ^b   La Rosa, Salvatore ^a   MacCari, Laura ^a   Marquis, Karen L ^b   Micco, Iolanda ^a   Nencini, Arianna ^a   Quinn, Joanna ^a   Robichaud, Albert J ^b   Roncarati, Renza ^a   Scali, Carla ^a   Terstappen, Georg C ^a   Turlizzi, Elisa ^a   Valacchi, Michela ^a   Varrone, Maurizio ^a   Zanaletti, Riccardo ^a   Zanelli, Ugo ^a   more..

^a Siena Biotech SpA   (Italy)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [6 (4 FLUOROPHENYL)PYRIDIN 3 YL] 3 (4 PIPERIDIN 1 YLBUTYL)UREA; BUNGAROTOXIN RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIZOCILPINE; SEN 34625; UNCLASSIFIED DRUG; UREA; WYE 103914;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CALCIUM TRANSPORT; COGNITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; ELECTROPHYSIOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE POTENTIAL; NONHUMAN; PREPULSE INHIBITION; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MODELS, MOLECULAR; NICOTINIC AGONISTS; PROTEIN CONFORMATION; PYRIDINES; RATS; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; UREA;

EID: 77953219713     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901692q     Document Type: Article

References (32)

1. Lindstrom, J. Neuronal nicotinic acetylcholine receptors Ion Channels 1996, 4, 377-450
2. Newhouse, P.; Singh, A.; Potter, A. Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders Curr. Top. Med. Chem. 2004, 4, 267-282 (Pubitemid 38842571)
3. Taly, A.; Corringer, P.-J.; Guedin, D.; Lestage, P.; Changeux, J.-P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discovery 2009, 8, 733-750
4. Decker, M. W.; Gopalakrishnan, M.; Meyer, M. D. The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions Expert Opin. Drug Discovery 2008, 3, 1027-1040
5. Gotti, C.; Riganti, L.; Vailati, S.; Clementi, F. Brain Neuronal Nicotinic Receptors as New Targets for Drug Discovery Curr. Pharm. Des. 2006, 12, 407-428
6. Acker, B. A.; Jacobsen, E. J.; Rogers, B. N.; Wishka, D. G.; Reitz, S. C.; Piotrowski, D. W.; Myers, J. K.; Wolfe, M. L.; Groppi, V. E.; Thornburgh, B. A.; Tinholt, P. M.; Walters, R. R.; Olson, B. A.; Fitzgerald, L.; Staton, T. J.; Raub, T. J.; Krause, M.; Li, K. S.; Hoffman, W. E.; Hajos, M.; Hurst, R. S.; Walker, D. P. Discovery of N-[(3 R,5 R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c] pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity Bioorg. Med. Chem. Lett. 2008, 18, 3611-3615
7. Pichat, P.; Bergis, O. E.; Terranova, J.-P.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C.; Steinberg, R.; Stemmelin, J.; Oury-Donat, F.; Avenet, P.; Griebel, G.; Scatton, B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia Neuropsychopharmacology 2007, 32, 17-34
8. Lippiello, P. M.; Bencherif, M.; Hauser, T. A.; Jordan, K. G.; Letchworth, S. R.; Mazurov, A. A. Nicotinic receptors as targets for therapeutic discovery Expert Opin. Drug Discovery 2007, 2, 1185-1203
9. Freedman, R.; Adams, C. E.; Leonard, S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia J. Chem. Neuroanat. 2000, 20, 299-306
10. Kem, W. R. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21) Behav. Brain Res. 2000, 113, 169-181
11. Tietje, K. R.; Anderson, D. J.; Bitner, R. S.; Blomme, E. A.; Brackemeyer, P. J.; Briggs, C. A.; Browman, K. E.; Bury, D.; Curzon, P.; Drescher, K. U.; Frost, J. M.; Fryer, R. M.; Fox, G. B.; Gronlien, J.; Hakerud, M.; Gubbins, E. J.; Halm, S.; Harris, R.; Helfrich, R. J.; Kohlhaas, K. L.; Law, D.; Malysz, J.; Marsh, K. C.; Martin, R. L.; Meyer, M. D.; Molesky, A. L.; Nikkel, A. L.; Otte, S.; Pan, L.; Puttfarcken, P. S.; Radek, R. J.; Robb, H. M.; Spies, E.; Thorin-Hagene, K.; Waring, J. F.; Ween, H.; Xu, H.; Gopalakrishnan, M.; Bunnelle, W. H. Preclinical Characterization of A-582941: A Novel α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enhancing Properties CNS Neurosci. Ther. 2008, 14, 65-82
12. Gaviraghi, G.; Ghiron, C.; Bothmann, H.; Roncarati, R.; Terstappen, G. C. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof. PCT Int. Appl. WO2006008133A2, 2006.
13. Haydar, S. N.; Ghiron, C.; Bettinetti, L.; Bothmann, H.; Comery, T. A.; Dunlop, J.; La Rosa, S.; Micco, I.; Pollastrini, M.; Quinn, J.; Roncarati, R.; Scali, C.; Valacchi, M.; Varrone, M.; Zanaletti, R. SAR and biological evaluation of SEN12333/WAY-317538: novel alpha 7 nicotinic acetylcholine receptor agonist Bioorg. Med. Chem. 2009, 17, 5247-5258
14. Roncarati, R.; Scali, C.; Comery, T. A.; Grauer, S. M.; Aschmies, S.; Bothmann, H.; Jow, B.; Kowal, D.; Gianfriddo, M.; Kelley, C.; Zanelli, U.; Ghiron, C.; Haydar, S.; Dunlop, J.; Terstappen. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders J. Pharmacol. Exp. Ther. 2009, 329, 459-468
15. Xiu, X.; Puskar, N. L.; Shanata, J. A. P.; Lester, H. A.; Dougherty, D. A. Nicotine Binding to Brain Receptors Requires a Strong Cation-φ Interaction Nature 2009, 458, 534-537
16. Compounds 2 and 3 were previously reported in ref 13.
17. Dunlop, J; Roncarati, R; Jow, B; Bothmann, H; Lock, T; Kowal, D; Bowlby, M; Terstappen, G. C. In vitro screening strategies for nicotinic receptor ligands Biochem. Pharmacol. 2007, 74, 1172-1181
18. Karlin, A.; Akabas, M. H. Towards a structural basis for the function of nicotinic acetylcholine recetors and their cousins Neuron 1995, 15, 1231-1244
19. Brejc, K.; van Dijk, W. J.; Klaassen, R. V.; Schuurmans, M.; van Der Oost, J.; Smit, A. B.; Sixma, T. K. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors Nature 2001, 411, 269-276
20. Lester, H. A.; Dibas, M. I.; Dahan, D. S.; Leite, J. F.; Dougherty, D. A. Cys-loop receptors: new twists and turns Trends Neurosci. 2004, 27, 329-336
21. Feng, M. R. Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo Curr. Drug Metab. 2002, 3, 647-657
22. Di, L.; Kerns, E.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232
23. Di, L.; Kerns, E.; Li, S.; Carter, G. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS Int. J. Pharm. 2007, 335, 1-11
24. Smith, D. A.; Jones, B. C.; Walker, D. K. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics Med. Res. Rev. 1996, 16, 243-266
25. Di, L.; Kerns, E.; Li, S.; Petusky, S. High Throughput Microsomal Stability Assay for Insoluble Compounds Int. J. Pharm. 2006, 317, 54-60
26. Di, L.; Kerns, E.; Ma, X.; Huang, Y.; Carter, G. Applications of high throughput microsomal stability assay in drug discovery Comb. Chem. High Throughput Screening 2008, 11 (6) 469-476
27. Yao, X.; Anderson, D. L.; Ross, S. A.; Lang, D. G.; Desai, B. Z.; Cooper, D. C.; Wheelan, P.; McIntyre, M. S.; Bergquist, M. L.; MacKenzie, K. I.; Becherer, J. D.; Hashim, M. A. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model Br. J. Pharmacol. 2008, 154, 1446-1456
28. Horenstein, N. A.; Leonik, F. M.; Papke, R. L. Multiple pharmacophores for the selective activation of nicotinic α7-type acetylcholine receptors Mol. Pharmacol. 2008, 74, 1496-1511
29. Still, W. C.; Kahn, M.; Mitra, A. J. Rapid chromatographic technique for preparative separations with moderate resolution J. Org. Chem. 1978, 43, 2923-2925
30. Crespi, C. L.; Miller, V. P.; Penman, B. W. Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450 Anal. Biochem. 1997, 248, 188-190
31. Palm, K.; Luthman, K.; Ros, J.; GraÌŠsjö, J.; Artursson, P. Effect of Molecular Charge on Intestinal Epithelial Drug Transport: pH-Dependent Transport of Cationic Drugs J. Pharmacol. Exp.Ther. 1999, 291, 435-443
32. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking J. Mol. Biol. 1997, 267, 727-748